HCA Healthcare (NYSE:HCA – Get Free Report) had its target price raised by research analysts at Robert W. Baird from $393.00 to $409.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird‘s target price indicates a potential downside of 9.39% from the stock’s previous close.
Several other research firms have also commented on HCA. BMO Capital Markets initiated coverage on shares of HCA Healthcare in a research report on Tuesday, September 22nd. They set an “outperform” rating and a $495.00 price target on the stock. JPMorgan Chase & Co. cut their target price on HCA Healthcare from $490.00 to $425.00 and set a “neutral” rating for the company in a research note on Thursday, August 20th. Cantor Fitzgerald restated an “overweight” rating on shares of HCA Healthcare in a research report on Friday, October 2nd. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of HCA Healthcare in a research note on Wednesday, July 15th. Finally, Jefferies Financial Group set a $450.00 price objective on HCA Healthcare in a research report on Tuesday, July 14th. Sixteen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $469.61.
Get Our Latest Analysis on HCA Healthcare
HCA Healthcare Trading Down 3.0%
HCA Healthcare (NYSE:HCA – Get Free Report) last issued its earnings results on Tuesday, October 27th. The company reported $7.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.65 by $0.57. The company had revenue of $19.85 billion during the quarter, compared to analysts’ expectations of $19.33 billion. During the same quarter in the previous year, the company earned $6.96 earnings per share. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. Analysts forecast that HCA Healthcare will post 29.51 earnings per share for the current year.
Hedge Funds Weigh In On HCA Healthcare
A number of hedge funds and other institutional investors have recently bought and sold shares of HCA. Interchange Capital Partners LLC grew its position in HCA Healthcare by 2.7% in the 3rd quarter. Interchange Capital Partners LLC now owns 4,213 shares of the company’s stock valued at $1,798,000 after acquiring an additional 111 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of HCA Healthcare during the third quarter worth about $43,000. Childress Capital Advisors LLC purchased a new position in shares of HCA Healthcare in the third quarter valued at approximately $315,000. North Dakota State Investment Board grew its holdings in shares of HCA Healthcare by 3.1% in the third quarter. North Dakota State Investment Board now owns 4,538 shares of the company’s stock valued at $1,937,000 after purchasing an additional 138 shares in the last quarter. Finally, Laurel Wealth Advisors LLC purchased a new stake in HCA Healthcare during the 3rd quarter worth approximately $40,000. 62.73% of the stock is currently owned by hedge funds and other institutional investors.
Trending Headlines about HCA Healthcare
Here are the key news stories impacting HCA Healthcare this week:
- Positive Sentiment: HCA reported third-quarter adjusted earnings of $7.22 per share and revenue of $19.85 billion, exceeding analyst estimates of $6.65 and $19.33 billion, respectively. Revenue increased 3.6% year over year, supported by higher admissions and emergency-room visits. HCA Healthcare beats quarterly profit estimates on demand for medical services
- Positive Sentiment: The company declared a quarterly dividend of $0.78 per share, or $3.12 annually, providing a modest shareholder-return benefit with a stated yield of approximately 0.7%.
- Neutral Sentiment: HCA maintained its existing guidance despite the mixed quarter. Analysts noted that strong admissions and revenue were partially offset by rising costs and lower surgical volumes, including a reported 5.4% decline in ambulatory surgery center volume. HCA Healthcare posts solid Q3 results, maintains guidance
- Negative Sentiment: Management signaled that 2027 earnings could be broadly flat, citing reduced Medicaid payments and reimbursement pressure. That outlook raised concerns about limited profit growth after the current year.
- Negative Sentiment: HCA expects a roughly $400 million impact from the increase in uninsured patients, adding to uncompensated-care expenses and weighing on margins. HCA takes $400M hit from rise in uninsured patients
- Negative Sentiment: The earnings call appears to have amplified investor concerns about reimbursement, payer mix, costs and future growth, overwhelming the quarter’s headline beat. A law firm also announced an investigation on behalf of HCA investors, adding a potential litigation overhang, although no claim has been established. HCA Healthcare shares slide following third-quarter earnings call
HCA Healthcare Company Profile
HCA Healthcare, Inc is a healthcare services company that operates hospitals, ambulatory surgery centers, emergency care facilities, physician practices and other healthcare sites. Its facilities provide a broad range of services, including acute and emergency care, surgery, cardiology, oncology, women’s and children’s services, behavioral health and outpatient care.
The company serves patients primarily across the United States through a network of healthcare facilities in numerous states.
Further Reading
- Five stocks we like better than HCA Healthcare
- Hidden in Plain Sight: 2 Earnings Winners Investors May Have Missed
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
